{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:22:25Z","timestamp":1772806945613,"version":"3.50.1"},"reference-count":69,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Respiratory Medicine"],"published-print":{"date-parts":[[2020,6,2]]},"DOI":"10.1080\/17476348.2020.1743180","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T23:09:50Z","timestamp":1584140990000},"page":"621-635","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of fluticasone propionate\/salmeterol for the treatment of COPD: a systematic review"],"prefix":"10.1080","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-069X","authenticated-orcid":false,"given":"Luigino","family":"Calzetta","sequence":"first","affiliation":[{"name":"Department of Experimental Medicine, University of Rome \u201cTor Vergata\u201d, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice Ludovica","family":"Ritondo","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome \u201cTor Vergata\u201d, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9707","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome \u201cTor Vergata\u201d, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome \u201cTor Vergata\u201d, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,4,4]]},"reference":[{"key":"cit0001","unstructured":"GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD \u2013 2020 Report; 2020 [cited 2020 Mar 7]. Available from: https:\/\/goldcopd.org\/wp-content\/uploads\/2019\/12\/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf"},{"key":"cit0002","unstructured":"US Food and Drug Administration. ADVAIR DISKUS (fluticasone propionate and salmeterol inhalation powder), for oral inhalation use. Reference ID: 4372031; 2000 [cited 2019 Oct 14]. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021077s061lbl.pdf"},{"key":"cit0003","unstructured":"European Medicines Agency. Seretide Diskus, EMEA\/306065\/2006; 2006 [cited 2019 Oct 14]. Available from: www.ema.europa.eu\/en\/medicines\/human\/referrals\/seretide-diskus"},{"key":"cit0004","unstructured":"GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, and prevention of COPD \u2013 2006 Report; 2006 [cited 2019 Oct 14]. Available from: https:\/\/www.who.int\/respiratory\/copd\/GOLD_WR_06.pdf"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.3109\/15412555.2014.995288"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S154097"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2018.07.009"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S210897"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1038\/npjpcrm.2016.2"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2019.1537"},{"key":"cit0011","unstructured":"US Food and Drug Administration. WIXELATM INHUBTM (fluticasone propionate and salmeterol inhalation powder), for oral inhalation use; 2019 [cited 2019 Oct 18]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208891Orig1s000lbl.pdf"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-7-16"},{"key":"cit0014","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. 16.1.2 General principles for dealing with missing data; 2011 [updated 2011 Mar]. Available from https:\/\/handbook-5-1.cochrane.org\/chapter_16\/16_1_2_general_principles_for_dealing_with_missing_data.htm"},{"key":"cit0015","unstructured":"European Commission. A guideline on summary of product characteristics (SmPC); 2009 [cited 2017 Jun 22]. Available from: http:\/\/ec.europa.eu\/health\/\/sites\/health\/files\/files\/eudralex\/vol-2\/c\/smpc_guideline_rev2_en.pdf"},{"issue":"7","key":"cit0016","first-page":"36","volume":"11","author":"Abr\u00e0moff MD","year":"2004","journal-title":"Biophotonics Int"},{"issue":"3","key":"cit0017","first-page":"471","volume":"124","author":"Sullivan KM","year":"2009","journal-title":"433021"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"cit0019","unstructured":"NCT00355342. Bone mineral density study in patients with chronic obstructive pulmonary disease. DISKUS\u00ae Inhaler is a Trademark of the GSK Group of Companies; 2006 [cited 2019 Sep 26]."},{"key":"cit0020","first-page":"2393","volume":"10","author":"Saito T","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"cit0021","unstructured":"NCT01751113. A 3 way cross-over study evaluating the effects of ADOAIR twice daily plus tiotropium bromide once daily compared with the individual treatments of japanese subjects (SCO116572); 2012 [cited 2019 Sep 26]."},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407154"},{"key":"cit0023","unstructured":"NCT00975195. Inhaled corticosteroid withdrawal in patients with chronic obstructive pulmonary disease; 2009 [cited 2019 Sep 26]."},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00126814"},{"key":"cit0025","unstructured":"NCT01555138. Comparison of indacaterol 150 mcg once daily (o.d.) with salmeterol\/fluticasone propionate 50 mcg\/500 mcg twice daily (b.i.d.) (INSTEAD); 2012 [cited 2019 Sep 26]."},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00074113"},{"key":"cit0027","unstructured":"NCT01124422. Fluticasone propionate\/salmeterol combination 250\/50 DISKUS in the exercise endurance time in patients with chronic obstructive pulmonary disease (ESWT); 2010 [cited 2019 Sep 26]."},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003048"},{"key":"cit0029","unstructured":"NCT00984659. Validation of a new shortness of breath with daily activities questionnaire in patients with chronic obstructive pulmonary disease; 2009 [cited 2019 Sep 26]."},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S152723"},{"key":"cit0031","unstructured":"NCT01762800. Evaluating the control of COPD symptoms in patients treated with tiotropium bromide 18mcg once daily alone, ADOAIR 50\/250mcg twice daily alone or ADOAIR 50\/250mcg plus tiotropium bromide 18mcg; 2013 [cited 2019 Sep 26]."},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.05.011"},{"key":"cit0033","unstructured":"NCT00530842. Effect of tiotropium plus salmeterol vs. fluticasone\/salmeterol on static lung volumes and exercise endurance in COPD; 2007 [cited 2019 Sep 26]."},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.05.016"},{"key":"cit0035","unstructured":"NCT00857766. A 16-week study to evaluate the effect of advair DISKUS\u2122 250\/50mcg on arterial stiffness in subjects with chronic obstructive pulmonary disease (COPD); 2009 [cited 2019 Sep 26]."},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.2174\/1874306401004010086"},{"key":"cit0037","unstructured":"NCT00633217. Advair HFA for chronic obstructive pulmonary disease(COPD); 2008 [cited 2019 Sep 26]."},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1177\/1753465809344870"},{"key":"cit0039","unstructured":"NCT00542880. Evaluation of onset of effect in patients with severe chronic obstructive pulmonary disease (COPD) treated with symbicort\u00ae compared to seretide\u00ae (SPEED); 2007 [cited 2019 Sep 26]."},{"key":"cit0040","unstructured":"NCT00784550. A 24-week study to evaluate the safety and efficacy of ADVAIR DISKUS\u00ae inhaler 250\/50mcg plus SPIRIVA HANDIHALER\u00ae inhaler versus SPIRIVA HANDIHALER\u00ae inhaler plus Placebo DISKUS\u00ae inhaler in subjects with chronic obstructive pulmonary disease (COPD). (ADC111114); 2008 [cited 2019 Sep 26]."},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201803-0405OC"},{"key":"cit0042","unstructured":"NCT02603393. Evaluation of the efficacy and safety of QVA149 (110\/50 \u03bcg o.d.) vs tiotropium (18 \u00b5g o.d.) + salmeterol\/fluticasone propionate FDC (50\/500 \u00b5g b.i.d.) in patients with moderate to severe COPD; 2015 [cited 2019 Sep 26]."},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13374"},{"key":"cit0044","unstructured":"NCT02516592. Assessment of switching from salmeterol\/fluticasone to indacaterol\/glycopyrronium in a symptomatic COPD patient cohort (FLASH); 2015 [cited 2019 Sep 26]."},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-014-0105-2"},{"key":"cit0046","unstructured":"NCT01110200. Chronic obstructive pulmonary disease (COPD) post-hospitalization study; 2010 [cited 2019 Sep 26]."},{"key":"cit0047","unstructured":"NCT02055352. Study to evaluate efficacy\/safety of combination budesonide\/indacaterol vs fluticasone\/salmeterol in patients with COPD (COMBINE); 2014 [cited 2019 Sep 26]."},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.12.020"},{"key":"cit0049","unstructured":"NCT00527826. Influence of salmeterol xinafoate\/fluticasone propionate (50\/500 \u00b5g BID) on the course of the disease and exacerbation frequency in COPD patients gold stage III and IV; 2007 [cited 2019 Sep 26]."},{"key":"cit0050","unstructured":"NCT00974246. The effect on depressive symptoms in ECF residents with COPD (DISK-02); 2009 cited 2019 Sep 26."},{"key":"cit0051","first-page":"453","volume":"8","author":"Betsuyaku T","year":"2013","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00772.x"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M141"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2013.852182"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2017.06.002"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.101855"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-018-0721-3"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01586-2018"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.12.016"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4388"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S185975"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S118867"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-019-0882-y"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.04.028"},{"key":"cit0065","unstructured":"GINA. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention; 2019 [cited 2020 Feb 6]. Available from: https:\/\/ginasthma.org\/wp-content\/uploads\/2019\/06\/GINA-2019-main-report-June-2019-wms.pdf"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200321020-00002"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1057\/palgrave.jgm.4940128"},{"issue":"4","key":"cit0068","first-page":"462","volume":"43","author":"King DR","year":"2002","journal-title":"Croat Med J"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0415-3"}],"container-title":["Expert Review of Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17476348.2020.1743180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T13:32:36Z","timestamp":1620480756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17476348.2020.1743180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,4]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,2]]}},"alternative-id":["10.1080\/17476348.2020.1743180"],"URL":"https:\/\/doi.org\/10.1080\/17476348.2020.1743180","relation":{},"ISSN":["1747-6348","1747-6356"],"issn-type":[{"value":"1747-6348","type":"print"},{"value":"1747-6356","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierx20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierx20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}